Jiayang Cai

Dr. Jiayang Cai


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Translational Oncology
Verified
Journal Article
Open access
JCJiayang Cai
Jiayang Cai
LGLUNGAO Gao
LUNGAO Gao
YWYixuan Wang
Yixuan Wang
YLYong Li
Yong Li
ZYZhang Ye
Zhang Ye
QCQianxue Chen
Qianxue Chen
• Our research firstly identified that TMBIM1 promotes proliferation and attenuates apoptosis via the p38/MAPK pathway in GBM. • We also revealed that TMBIM1 regulates the sensitivity of GBM cells to TMZ. Our research will provide an important basis for future intensive molecular mechanism research in GBM and TMBIM1 might be a potential therapeutic target for treating GBM.

15 April 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SYShao-Ying Yang
Shao-Ying Yang
MJMing-Liang Jin
Ming-Liang Jin
LALisa Andriani
Lisa Andriani
QZQian Zhao
Qian Zhao
YLYun-Xiao Ling
Yun-Xiao Ling
DLDa-Qiang Li
Da-Qiang Li
Hormone receptor–positive and human epidermal growth factor receptor 2–negative breast cancer (HR + /HER2 − BC) is the most common subtype, with a high risk of long-term recurrence and metastasis. Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is a standard treatment for advanced/metastatic HR + /HER2 – BC, but resistance remains a major clinical challenge. We report that kinesin family member C2 ( KIFC2 ) was amplified in approximately 50% of patients with HR + /HER2 – BC, and its high expression was associated with poor disease outcome, increased tumor protein p53 ( TP53 ) somatic mutation, and active pyrimidine metabolism. Functional assays revealed that depletion of KIFC2 suppressed growth and enhanced sensitivity of HR + /HER2 – BC cells to tamoxifen and CDK4/6 inhibitors. Mechanistically, KIFC2 stabilized CDK4 by enhancing its interaction with ubiquitin-specific peptidase 9 X-linked (USP9X). Importantly, reexpression of CDK4 in KIFC2-depleted cells partially rescued the decreased growth and increased sensitivity to tamoxifen and CDK4/6 inhibitors caused by KIFC2 depletion. Clinically, high KIFC2 mRNA expression was negatively associated with the survival rate of patients with HR + /HER2 – BC who received adjuvant ET alone or in combination with CDK4/6 inhibitors. Collectively, these findings identify an important role for KIFC2 in HR + /HER2 – BC growth and therapeutic resistance, and support its potential as a therapeutic target and predictive biomarker.

29 April 2026 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
JCJiayang Cai
Jiayang Cai
YZYin-Ling Zhang
Yin-Ling Zhang
FZFang-Lin Zhang
Fang-Lin Zhang
QZQian Zhao
Qian Zhao
MMMeng-Ke Ma
Meng-Ke Ma
ZSZhi-Ming Shao
Zhi-Ming Shao
Purpose Triple-negative breast cancer (TNBC) displays an aggressive clinicopathological profile. Despite cytotoxic chemotherapy being the primary systemic therapy, complete responses are achieved in fewer than 30% of patients, highlighting the need for new therapeutic targets and a deeper understanding of disease-driving mechanisms. Methods This study identified key oncogenic factors in TNBC through multi-omics differential analyses. Cell proliferation, migration, and invasion abilities were assessed using CCK-8, colony formation, and transwell migration and invasion assays. Quantitative proteomics was applied to profile downstream protein alterations following HDHD5 knockdown. Western blotting and RT-qPCR were used to examine expression levels in different samples. Xenograft tumor model was employed to investigate the in vivo functions of HDHD5. Results HDHD5 was highly expressed in TNBC and its elevated expression was associated with poor patient prognosis. Functional studies demonstrated that HDHD5 promotes TNBC cell proliferation and colony formation, as well as enhances cell migration and invasion. Mechanistically, HDHD5 facilitates epithelial–mesenchymal transition (EMT) associated phenotypes and promotes migratory and invasive capacities in TNBC cell lines, at least in part, through regulation of S100A4. Consistently, HDHD5 promoted TNBC tumor growth both in vitro and in vivo via S100A4. Conclusion Our study reveals HDHD5 as a previously unrecognized driver of tumor progression in TNBC and highlights its potential as a therapeutic target and prognostic biomarker for this aggressive breast cancer subtype.